Liposomes, Protein and Peptide Drug Delivery Systems

Reference

1. Grubber, S.M. Liposome Biophysics Therapeutics, Marcel Dekker: New York, 1987.
2.  Bangham, A.D. Liposomes in Biological Systems, John Wiley and Sons: Chichester, 1980.
3.  Jayakrishnan, A.; Latha, M.S. Controlled and Novel Drug Delivery, B.S. Pub: New Delhi, 1997.
4.  Gregoriadis, G. Methods Enzymol., 1976, 44, 278.
5.  T. Hamada and K. Yoshikawa, Materials, 2012, 5, 2292-2305.
6.  F. de Meyer and B. Smit, Proc. Natl. Acad. Sci., 2009, 106, 3654.
7.  T. Subramani and H. Ganapathyswamy, J. Food Sci. Technol., 2020, 57, 3545-3555.
8.  T. Subramani and H. Ganapathyswamy, J. Food Sci. Technol., 2020, 57, 3545-3555.
9.   Allen TM, Hansen C, Martin F, Redemann C, YauYoung A. 1991. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1066:29±36.
10. Beauchamp C, Daddona PE, Menapace DP. 1984. Properties of a novel PEG derivative of calf adenosine deaminase. Adv Exp Med Biol 165
11. Torchilin VP. 1994. Immunoliposomes and PEGylated immunoliposomes: possible use of targeted delivery of imaging agents. Immunomethods 4: 244±258.
12. Risbo J, Jorgensen K, Sperotto MM, Mouritsen OG.1997. Phase behavior and permeability properties of phospholipid bilayers containing a short-chain phospholipidpermeability enhancer. Biochim Biophys Acta 1329:85±96.
13. Corvera E, Mouritsen OG, Singer MA, ZuckermannMJ. 1992. The permeability and the effect of acylchain length for phospholipid bilayers containing cholesterol: Theory and experiment. Biochim Biophys Acta 1107:261±270.
14. Dunnick . J. K; Rookie, J.D ; Aragon, S ; kriss , J. P. Cancer, Res, 1976, 36, 2385-2389.
15.  Posted, G. Liposomes in Biological system, John Wiley and sons, 1980.
16.  Amaranth Sharma*, Uma S. Sharma ; Liposomes in drug delivery: progress and limitations, Department of Experimental Therapeutics, Roswell Park Cancer Institute, and Department of Pharmaceutics, SUNY at Buffalo, Buffalo, NY, USA.Gluck, R.; Mischelar, R.; Brantschen, S.; Just, M.; Althaus, B.; Cryz, S. J. J. Clin. Invest., 1992, 90, 2491.
17.  Moghimi SM (2002) Chemical camouflage of nanospheres with a poorly reactive surface: Towards development of stealth and targetspecific nanocarriers. Biochim Biophys Acta 1590:131–139.
18.  Mc Cayley , J.A.; Flory’s Book.; Mc Comb. T.G. Biochim. Biophys. Acta, 1992, 30,112.
19.  Satyanarayan U, Chakrapani U, Biochemistry, 3rd Ed., Books and allied (p) Ltd., Kolkata, 2008; 43-44.
20.  Banga A.K. and Chein Y.W, Systemic delivery of therapeutic peptides and proteins, Int. J. Pharmaceutics, 1988; 48: 15?50
21.  Meyer et al. Transdermal delivery of human insulin to albino rabbits using electrical current. Am. J. Med. Sci., 1989; 297: 321?325.
22.  Tahami. Alkhaled and Singh J., Recent patent on drug delivery and formulation, 2007; 1:65?71.
23.  Lin SY and Yang JC, Effect of _-cyclodextrin on the in vitro permeation rate and in vivo rectal absorption of acetaminophen hydrogel preparations. Pharm. Acta Helv., 1990; 65:262-268.
24.  Arima H et al. Use of water soluble _-cyclodextrin derivatives as carriers of anti inflammatory drug bi phenylyl acetic acid in rectal delivery. Yakugaku Zasshi. 1992; 112:65-72.    
25.  Brouard A et al. Rectal administration of carbamazepine gel. Clin. Pharm. 1990; 9:13–14.
26.  Maloney CM et al. The rectal administration of MS contin: clinical implications of use in end stage therapy cancer. Am. J. Hosp Care. 1989; 6(4): 34-35. 
27.  Batul N et al. Pharmacokinetics of two novel rectal controlled release morphine formulations. J. Pain Symptom Manage. 1992; 7(7): 400-405.
28.  Warren DE. Practical use of rectal medications in palliative care. J. Pain Symptom Manage. 1996; 11(6): 378-387.
29.  Sarwar, G. The protein digestibility-corrected amino acid score method overestimates quality of proteins containing antinutritional factors and of poorly digestible proteins supplemented with limiting amino acids in rats. Journal of Nutrition 1997; 127: 758-764.
30.  Tikkanen, M.J., Wahala, K., Ojala, S., Vihma, V., and Adlecrerutz, H. Effect of soybean phytoestrogen intake on low density lipoprotein oxidation resistance. Proclamations of the National Academy of Science 1998; 95: P3106-P3110.
31.  Higuchi T. Mechanism of sustained-action medication. J Pharm Sci 1963; 52: 1145–1149.
32.  Kwok WY, Kiparisider C, Yuet P, Harris TJ and Goosen MFA. Mathematical modelling of protein diffusion in microcapsules: a comparison with experimental results. Can J Chem Eng 1990; 68.
33.  Okhamafe AO and Goosen MFA. Modulation of membrane permeability. In: Kuhtrelber WM, Lanza RP and Chick WL(Eds.). Cell Encapsulation Technology and Therapeutics. Birkhäuser Boston Inc, 1999; 53–62.
34.  G. P. Li, Z. G. Liu, B. Liao and N. S. Zhong, ?Induction of Th1-Type Immune Response by Chitosan Nanoparti-cles Containing Plasmid DNA Encoding House Dust Mite Allergen Der p 2 for Oral Vaccination in Mice,? Cellular & Molecular Immunology, 2009; 6(1): 45-50. doi:10.1038/cmi.2009.6
35.  I. S. Kim, S. K. Lee, Y. M. Park, Y. B. Lee and S. C. Shin, ?Physicochemical Characterization of Poly(L-lactic acid) and Poly(D,L-lactide-co-glycolide) Nanoparticles with Polyethylenimine as Gene Delivery Carrier,? Interna-tional Journal of Pharmaceutics, 2005; 298(1): 255-262. doi:10.1016/j.ijpharm.2005.04.017
36.  ANGELINI, “EPAXAL®—Vaccine for Active Immuni- sation against Hepatitis A,”2011. http://www.angelini.it/public/schedepharma/epaxal.htm
37.  J. L. Italia, A. Sharp, K. C. Carter, P. Warn and M. N. V. R. Kumar, ?Peroral Amphotericin B Polymer Nanoparti-cles Lead to Comparable or Superior in Vivo Antifungal Activity to That of Intravenous Ambisome® or Fungizone™,? PLoS One, 2011; 6(10): 8. doi:10.1371/journal.pone.0025744
38. R. Rupp, S. L. Rosenthal and L. R. Stanberry, ?VivaGel (SPL7013 Gel): A Candidate Dendrimer—Microbicide for the Prevention of HIV and HSV Infection,? International Journal of Nanomedicine, 2007; 2(4): 561-566.
39.  H. Sarin, ?Recent Progress towards Development of Ef-fective Systemic Chemotherapy for the Treatment of Ma-lignant Brain Tumors,? Journal of Translational Medi-cine, 2009; 7: 77. doi:10.1186/1479-5876-7-77
40.  National Diabetes Data Group, Diabetes in America: Diabetes Data Compiled 1984. Bethesda Md. NIH. 85, 1985; 146X.
41.  Calceti, P. et al. Development and in vivo evaluation of an oral insulin-PEG delivery system. Eur. J. Pharm. Sci., 2004; 22: 315–323
42.  Basu, A. et al. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjugate Chem. 2006; 17: 618–630
43. Wang, J. et al. Reversible lipidization for the oral delivery of salmon calcitonin. J. Control. Release, 2003; 26: 369–380
44.  Kipnes, M. et al. Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes. Diabetes Care, 2003; 26: 421–42